

*Cultivating Compassion*



DURDANS  
HOSPITAL

FINANCIAL STATEMENTS  
CEYLON HOSPITALS PLC

FOR THE 3RD QUARTER ENDED 31ST DECEMBER 2024

## Consolidated Statement of Profit or Loss and Other Comprehensive Income

	Group		Company		Group		Company	
	03 Months Ended 31/12/2024 Unaudited Rs. '000	03 Months Ended 31/12/2023 Unaudited Rs. '000	03 Months Ended 31/12/2024 Unaudited Rs. '000	03 Months Ended 31/12/2023 Unaudited Rs. '000	09 Months Ended 31/12/2024 Unaudited Rs. '000	09 Months Ended 31/12/2023 Unaudited Rs. '000	09 Months Ended 31/12/2024 Unaudited Rs. '000	09 Months Ended 31/12/2023 Unaudited Rs. '000
<b>Revenue</b>	<b>2,501,636</b>	2,330,267	<b>1,437,019</b>	1,367,512	<b>7,207,323</b>	6,791,241	<b>4,219,026</b>	3,951,159
Cost of Sales	(928,445)	(1,032,743)	(541,174)	(638,275)	(2,918,958)	(3,092,175)	(1,725,788)	(1,848,787)
<b>Gross Profit</b>	<b>1,573,191</b>	1,297,524	<b>895,846</b>	729,237	<b>4,288,366</b>	3,699,066	<b>2,493,238</b>	2,102,372
Other Operating Income	1,990	(561)	14,834	17,029	60,303	50,716	45,848	46,229
Administrative Expenses	(928,236)	(842,211)	(599,751)	(509,932)	(2,737,013)	(2,461,868)	(1,741,301)	(1,520,461)
Other Operating Expenses	(321,791)	(318,348)	(154,782)	(159,310)	(960,335)	(933,670)	(497,174)	(459,881)
<b>Results from Operating Activities</b>	<b>339,315</b>	70,824	<b>152,881</b>	74,789	<b>651,321</b>	354,244	<b>300,610</b>	168,259
Finance Cost	(55,534)	(23,288)	(66,742)	(31,442)	(200,307)	(110,817)	(228,392)	(101,958)
Finance Income	224,008	60,415	5,336	1,449	247,388	195,615	154,067	173,241
<b>Profit before Taxation</b>	<b>493,628</b>	173,531	<b>94,740</b>	47,031	<b>698,402</b>	439,042	<b>226,285</b>	239,542
Taxation	(38,400)	(61,737)	(25,900)	(34,138)	(137,050)	(194,984)	(58,176)	(75,896)
<b>Net Profit after Taxation</b>	<b>455,228</b>	111,794	<b>68,840</b>	12,893	<b>561,353</b>	244,058	<b>168,109</b>	163,646
<b>Other Comprehensive Income</b>								
<b>Items will not be reclassified to profit or loss</b>								
Net Change in Fair Value on Equity								
Investments at FVTOCI	15,015	(529)	(140)	-	10,853	1,721	547	(2,021)
Other Comprehensive Income for the period	15,015	(529)	(140)	-	10,853	1,721	547	(2,021)
<b>Total Comprehensive Income for the period</b>	<b>470,243</b>	111,265	<b>68,701</b>	12,893	<b>572,204</b>	245,779	<b>168,656</b>	161,625
Profit Attributable to:								
Equity Holders of the Parent	397,928	100,730	68,840	12,893	482,333	218,742	168,109	163,646
Non-Controlling Interest	57,299	11,064	-	-	79,019	25,316	-	-
	<b>455,228</b>	111,794	<b>68,840</b>	12,893	<b>561,352</b>	244,058	<b>168,109</b>	163,646
Total Comprehensive Income Attributable to:								
Equity Holders of the Parent	410,088	100,301	68,701	12,893	491,244	219,758	168,656	161,625
Non-Controlling Interest	60,155	10,964	-	-	80,961	26,021	-	-
	<b>470,242</b>	111,265	<b>68,701</b>	12,893	<b>572,204</b>	245,779	<b>168,656</b>	161,625
<b>Earnings per Share - Basic</b>	<b>9.67</b>	2.80	<b>1.67</b>	0.36	<b>11.73</b>	6.08	<b>4.09</b>	4.55

The above figures are provisional and subject to audit.

**CEYLON HOSPITALS PLC**

Financial Statements for the nine months ended 31st December 2024

**Consolidated Statement of Financial Position**


<b>GROUP</b>		<b>COMPANY</b>		<b>GROUP</b>		<b>COMPANY</b>	
Audited	Audited			Unaudited	Unaudited	Unaudited	Unaudited
As at	As at			As at	As at	As at	As at
31/03/2024	31/03/2024			31/12/2024	31/12/2023	31/12/2024	31/12/2023
Rs. '000	Rs. '000			Rs. '000	Rs. '000	Rs. '000	Rs. '000
<b>ASSETS</b>							
<b>Non-Current Assets</b>							
11,582,383	8,241,211	Property, Plant and Equipment		11,505,444	7,825,791	8,251,566	4,671,249
72,479	66,091	Capital Work in Progress		94,951	3,264,316	58,582	3,259,263
1,365	-	Intangible Assets		1,171	1,600	-	-
363,571	363,571	Right of Use Assets		361,013	291,029	361,013	291,029
-	1,493,625	Investments in Subsidiary		-	-	1,493,625	1,457,821
289,393	72,066	Other Financial Assets		196,378	298,078	72,408	79,666
12,309,191	10,236,564			12,158,956	11,680,814	10,237,194	9,759,028
814,311	642,259	Inventories		816,089	863,974	620,120	666,002
312,866	199,904	Trade and Other Receivables		364,579	429,321	205,744	246,789
291,390	164,155	Prepayments		364,803	582,779	175,006	287,999
5,385	66,372	Amount Due from Related Parties		6,857	5,415	113,521	85,252
899,205	45,529	Other Financial Assets		1,420,193	713,230	194,234	63,780
44,254	37,260	Tax Refund Due		32,329	13,416	28,350	13,416
366,451	212,125	Cash and Cash Equivalents		183,314	297,717	101,827	227,324
2,733,862	1,367,604			3,188,163	2,905,852	1,438,801	1,590,562
15,043,053	11,604,168	<b>Total Assets</b>		15,347,120	14,586,666	11,675,995	11,349,590
<b>EQUITY AND LIABILITIES</b>							
<b>Equity Attributable to Equity holders of the parent</b>							
1,142,798	1,142,798	Stated Capital		1,692,704	1,142,798	1,692,704	1,142,798
2,290,344	1,742,664	Revaluation Reserve		2,290,345	2,290,344	1,742,663	1,742,664
74,340	(659)	Fair Value Reserve		83,251	77,860	(112)	4,291
4,595,643	2,963,955	Revenue Reserves		5,002,943	4,397,757	3,057,032	2,893,103
8,103,125	5,848,758			9,069,242	7,908,759	6,492,288	5,782,856
733,044	-	Non-Controlling Interests		784,716	721,719	-	-
8,836,169	5,848,758	<b>Total Equity</b>		9,853,958	8,630,478	6,492,288	5,782,856
<b>Non-Current Liabilities</b>							
1,989,051	1,872,910	Interest Bearing Loans and Borrowings		1,121,049	2,312,621	1,008,452	2,666,305
279,087	279,087	Lease Liability		268,823	-	268,823	-
-	28,580	Deferred Revenue		-	-	27,162	29,051
227,265	203,793	Retirement Benefit Obligations		254,373	210,488	231,286	189,323
1,389,826	1,063,004	Deferred Tax Liabilities		1,447,030	1,338,997	1,112,260	1,032,120
-	467,500	Amount Due to Related Parties		-	-	446,250	-
3,885,229	3,914,874			3,091,275	3,862,106	3,094,233	3,916,799
<b>Current Liabilities</b>							
542,805	413,050	Bank Overdraft		574,005	458,265	456,747	368,252
488,626	428,928	Interest Bearing Loans and Borrowings		471,855	506,151	428,929	485,552
120,416	120,416	Lease Liability		120,416	-	120,416	-
1,027,015	551,023	Trade and Other Payables		1,198,530	1,069,881	595,334	507,835
-	-	Taxation Payable		26,991	45,291	-	20,635
142,793	327,119	Amount Due to Related Parties		10,090	14,494	488,050	267,661
2,321,655	1,840,536			2,401,887	2,094,082	2,089,475	1,649,935
15,043,053	11,604,168	<b>Total Equity and Liabilities</b>		15,347,120	14,586,666	11,675,995	11,349,590


The above figures are provisional and subject to audit.

  
**Thusitha Rubasinghe**  
 Chief Financial Officer

The Board of Directors is responsible for the preparation and presentation of these Financial Statements.

Signed for and on behalf of the Board by

  
**A E Tudawe**  
 Chairman

  
**U D Tudawe**  
 Director

13th February 2025

## Consolidated Statement of Changes in Equity

Group	Attributable to equity holders of the parent					Non-Controlling Interests Rs. '000	Total Equity Rs. '000
	Stated Capital	Revaluation Reserve	Fair Value Reserve	Revenue Reserves	Total		
	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000		
<b>Balance as at 31st March 2023 -Audited</b>	<b>1,142,798</b>	<b>2,290,344</b>	<b>76,843</b>	<b>4,261,864</b>	<b>7,771,849</b>	<b>729,501</b>	<b>8,501,350</b>
Net Profit for the year ended 31 March 2024	-	-	-	417,194	417,194	36,618	453,812
<b>Other Comprehensive Income</b>							
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	(2,503)	-	(2,503)	1,037	(1,466)
Actuarial Gain on Gratuity Valuation	-	-	-	673	673	(265)	408
Deferred Tax effect on Gratuity Valuation	-	-	-	(755)	(755)	(45)	(800)
<b>Total Comprehensive Income for the year ended 31 March 2024</b>	<b>-</b>	<b>-</b>	<b>(2,503)</b>	<b>417,112</b>	<b>414,609</b>	<b>37,345</b>	<b>451,954</b>
<b>Transactions with Owners in their capacity as Owners</b>							
Rights Issue Expenses	-	-	-	(557)	(557)	-	(557)
Dividend Paid - Ordinary Shares	-	-	-	(82,776)	(82,776)	(33,802)	(116,578)
	<b>-</b>	<b>-</b>	<b>-</b>	<b>(83,333)</b>	<b>(83,333)</b>	<b>(33,802)</b>	<b>(117,135)</b>
<b>Balance as at 31st March 2024 -Audited</b>	<b>1,142,798</b>	<b>2,290,344</b>	<b>74,340</b>	<b>4,595,643</b>	<b>8,103,124</b>	<b>733,044</b>	<b>8,836,169</b>
Net Profit for the nine months ended 31 December 2024	-	-	-	482,333	482,333	79,019	561,352
<b>Other Comprehensive Income</b>							
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	8,911	-	8,911	1,942	10,853
<b>Total Comprehensive Income for the quarter ended 31 December 2024</b>	<b>-</b>	<b>-</b>	<b>8,911</b>	<b>482,333</b>	<b>491,244</b>	<b>80,961</b>	<b>572,204</b>
<b>Transactions with Owners in their capacity as Owners</b>							
Shares issued at Rights Issue	549,906	-	-	-	549,906	-	549,906
Rights Issue Expenses	-	-	-	(3,053)	(3,053)	-	(3,053)
Dividend Paid - Ordinary Shares	-	-	-	(71,980)	(71,980)	(29,289)	(101,269)
<b>Balance as at 31st December 2024</b>	<b>1,692,704</b>	<b>2,290,344</b>	<b>83,251</b>	<b>5,002,943</b>	<b>9,069,242</b>	<b>784,716</b>	<b>9,853,958</b>
<b>Company</b>							
	Stated Capital	Revaluation Reserve	Fair Value Reserve	Revenue Reserves	Total		
	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000		
<b>Balance as at 31st March 2023 - Audited</b>	<b>1,142,798</b>	<b>1,742,664</b>	<b>6,312</b>	<b>2,812,305</b>	<b>5,704,079</b>		
Net Profit for the year ended 31 March 2024	-	-	-	233,631	233,631		
<b>Other Comprehensive Income</b>							
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	(6,971)	-	(6,971)		
Actuarial Gain on Gratuity Valuation	-	-	-	1,931	1,931		
Deferred Tax Effect on Gratuity Valuation	-	-	-	(579)	(579)		
<b>Total Comprehensive Income for the year ended 31 March 2024</b>	<b>-</b>	<b>-</b>	<b>(6,971)</b>	<b>234,983</b>	<b>228,012</b>		
<b>Transactions with Owners in their capacity as Owners</b>							
Rights Issue Expenses	-	-	-	(557)	(557)		
Dividend Paid - Ordinary Shares	-	-	-	(82,776)	(82,776)		
	<b>-</b>	<b>-</b>	<b>-</b>	<b>(83,333)</b>	<b>(83,333)</b>		
<b>Balance as at 31st March 2024 - Audited</b>	<b>1,142,798</b>	<b>1,742,664</b>	<b>(659)</b>	<b>2,963,955</b>	<b>5,848,758</b>		
Net Profit for the nine months ended 31 December 2024	-	-	-	168,109	168,109		
<b>Other Comprehensive Income</b>							
Net Change in Fair Value on Equity Investments at FVTOCI	-	-	547	-	547		
<b>Total Comprehensive Income for the quarter ended 31 December 2024</b>	<b>-</b>	<b>-</b>	<b>547</b>	<b>168,109</b>	<b>168,656</b>		
<b>Transactions with Owners in their capacity as Owners</b>							
Shares issued at Rights Issue	549,906	-	-	-	549,906		
Rights Issue Expenses	-	-	-	(3,053)	(3,053)		
Dividend Paid - Ordinary Shares	-	-	-	(71,980)	(71,980)		
<b>Balance as at 31st December 2024</b>	<b>1,692,704</b>	<b>1,742,664</b>	<b>(112)</b>	<b>3,057,032</b>	<b>6,492,288</b>		

## Consolidated Statement of Cash Flows

Group Audited 12 Months Ended 31/03/2024 Rs '000	Company Audited 12 Months Ended 31/03/2024 Rs '000		Group Unaudited 09 Months Ended 31/12/2024 Rs '000	Unaudited 09 Months Ended 31/12/2023 Rs '000	Company Unaudited 09 Months Ended 31/12/2024 Rs '000	Unaudited 09 Months Ended 31/12/2023 Rs '000
<b>Cash Flows from/ (Used in) Operating Activities</b>						
658,886	293,937	Net Profit Before Income Tax Expenses	698,402	439,042	226,285	239,542
		Adjustments for :				
26,519	18,537	Inventory Write-off/(Write in)	14,893	72,670	15,047	65,369
49,230	39,240	Bad Debts Write-off	16,873	12,452	4,563	12,452
442,576	230,162	Depreciation Charge	416,381	333,216	247,227	164,127
124,577	124,577	Amortisation of Right of use assets	95,550	91,040	95,550	90,882
(99,656)	(171,816)	Finance Income	(247,388)	(106,599)	(154,067)	(173,241)
144,669	147,984	Finance Cost	200,307	110,817	228,392	101,958
-	(1,890)	Amortisation of Deferred Rent Expenses/(Income)	-	-	(1,418)	(1,418)
(17,755)	(1,550)	(Profit)/ Loss on Disposal of Property, Plant and Equipment	(29,500)	(4,880)	-	-
-	-	(Profit)/ Loss on Disposal of Financial Instruments	(2,935)	(4,877)	(3,085)	(4,390)
(102,117)	(2,079)	Fair value (Gain)/Loss on Financial Instruments	-	(82,542)	-	(589)
(1,113)	(1,113)	Unclaimed Dividends	-	(1,113)	-	(1,113)
(160)	-	Creditors written back	-	-	-	-
19,814	-	Unclaimed VAT	-	-	-	-
57,627	50,804	Provision for Defined Benefit Plans	48,219	30,806	44,162	27,026
1,303,097	726,793	Operating Profit before Working Capital Changes	1,210,801	890,032	702,655	520,605
179,302	146,797	(Increase)/Decrease in Inventories	(16,671)	83,487	7,093	76,222
330,379	130,061	(Increase)/Decrease in Trade and Other Receivables	(141,998)	(20,872)	(21,286)	(13,879)
147,995	100,441	Increase/(Decrease) in Trade and Other Payables	226,406	190,543	44,445	72,253
142,738	252,236	(Increase)/Decrease Related Party Dues	(137,072)	14,409	92,396	208,202
2,103,511	1,356,328	Cash Generated from Operations	1,141,466	1,157,599	825,304	863,403
(144,669)	(120,885)	Finance Cost Paid	(200,306)	(89,878)	(224,792)	(77,081)
(35,369)	(27,807)	Defined Benefit Plan Costs Paid	(21,111)	(25,732)	(16,602)	(20,430)
(198,041)	(60,608)	Income Tax/WHT Paid	(49,234)	(197,246)	(11)	(61,876)
1,725,432	1,147,028	Net Cash from Operating Activities	870,815	844,743	583,898	704,016
<b>Cash Flows from/ (used in) Investing Activities</b>						
(958,307)	(480,682)	Acquisition of Property, Plant and Equipment	(371,219)	(1,112,857)	(250,073)	(861,795)
(827,135)	(823,939)	Acquisition of Capital work in progress	-	-	-	-
(1,600)	-	Purchase of Intangible Assets	-	-	-	-
6,430	1,550	Proceeds from Sale of Property, Plant and Equipment	29,500	4,880	-	-
42,879	-	Proceeds on Sale of Shares/Units	-	-	-	-
(50,184)	(32,175)	(Acquisition)/ Disposal of other Investments	(215,781)	162,395	(141,636)	(19,245)
99,657	171,816	Income from Investments	46,048	106,599	146,656	171,162
(1,688,260)	(1,163,430)	Net Cash Flows from/ (used in) Investing Activities	(511,452)	(838,983)	(245,053)	(709,878)
<b>Cash Flows from/ (used in) Financing Activities</b>						
375,000	360,000	Receipts from Interest Bearing Loans and Borrowings	-	300,000	-	300,000
(254,128)	(194,712)	Re-payments to Interest Bearing Loans and Borrowing	(916,029)	(175,008)	(864,459)	(129,952)
-	-	Purchase of Intangible Assets	-	(1,600)	-	-
(154,378)	(154,379)	Lease Rent Payment	(103,255)	(110,165)	(103,255)	(110,165)
-	-	Proceeds on Shares issued at Rights Issue	549,906	-	549,906	-
(557)	(557)	Right Issue Expenses	(3,053)	(73)	(3,053)	(73)
(116,579)	(82,776)	Dividends Paid	(101,269)	(116,578)	(71,980)	(82,776)
(150,642)	(72,424)	Net Cash Flows from/ (used in) Financing Activities	(573,700)	(103,424)	(492,841)	(22,966)
(113,470)	(88,825)	Net Increase/ (Decrease) in Cash and Cash Equivalents	(214,337)	(97,664)	(153,995)	(28,828)
(62,884)	(112,100)	Cash and Cash Equivalents at the Beginning of the Year	(176,354)	(62,884)	(200,925)	(112,100)
(176,354)	(200,925)	Cash and Cash Equivalents at the End of the Period	(390,691)	(160,548)	(354,920)	(140,928)
<b>Analysis of Cash and Cash Equivalents</b>						
(542,805)	(413,050)	Bank Overdraft	(574,005)	(458,265)	(456,747)	(368,252)
366,451	212,125	Cash in Hand and at Bank	183,314	297,717	101,827	227,324
(176,354)	(200,925)		(390,691)	(160,548)	(354,920)	(140,928)

## Explanatory Notes

## 01. CORPORATE INFORMATION

Ceylon Hospitals PLC is a public limited company incorporated and domiciled in Sri Lanka and listed on the Colombo Stock Exchange. Ordinary shares of the company are listed on the Colombo Stock Exchange.

## 02. INTERIM CONDENSED FINANCIAL STATEMENTS

The financial statements for the nine months ended 31 December 2024, includes "the Company" referring to Ceylon Hospitals PLC, as the holding company and "the Group" referring to the companies whose accounts have been consolidated therein.

### 03. APPROVAL OF FINANCIAL STATEMENTS

The interim condensed financial statements of the Group and the Company for the nine months ended 31 December 2024 were authorised for issue by the Board of Directors on 13 February 2025.

#### 04. BASIS OF PREPARATION AND CHANGES TO ACCOUNTING POLICIES

### 4.1 Basis of preparation

The interim condensed financial statements for the nine months ended 31 December 2024 have been prepared in accordance with LKAS 34 Interim Financial Reporting.

The interim condensed financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 March 2024.

## 4.2 Fair value measurement and related fair value disclosures

All unquoted equity shares taking into their fair values, classified as Level 3 within the fair value hierarchy according to fair valuation methodology. Fair value would not significantly vary if one or more of the inputs were changed. The fair value of the financial assets and financial liabilities don't change materially to their carrying value.

Investments in quoted shares, Investments in Debentures and Refundable deposits are classified under non current financial assets while Investments in Unit Trusts, Investment in quoted shares (Trading) and Investments in Fixed Deposits are classified under current financial assets.

[illegible]

05. There were no contingent liabilities as at the Balance Sheet date which would require adjustment or disclosure in the Financial Statements other than what is disclosed in the Annual Report 2023/2024.

## 06. Events occurring after the Balance Sheet date

The amalgamation of Durdans Heart Centere (Pvt.) Ltd. with Ceylon Hospitals took place on 1st January 2025 and is effective thereon.

07. Related party transactions for the nine months ended 31 December 2024 were reviewed by the Related Party Transactions Review Committee and it was decided there were no transactions requiring Board Approval, immediate CSE disclosure or Shareholder approval.

**CEYLON HOSPITALS PLC**  
**Related Party Transactions**  
**For the nine months ended 31st December 2024**

Name of the Related Party	Relationship	Transactions	Nature	Aggregate Value of Related Party Transactions Rs'000
Durdans Management Services Ltd	Ultimate Parent	Management fee Paid Debenture Interest Received	Recurrent Recurrent	71,802 3,403
Durdans Medical and Surgical Hospital (Pvt) Ltd	Subsidiary	Sales of Drugs and consumables Rendering of medical services Sharing of utilities and other cost Dividend received  Purchases of Drugs and consumables Receiving of medical services Receiving of utilities and other cost	Recurrent Recurrent Recurrent  Recurrent Recurrent Recurrent	30,522 104,340 422,937 134,043  42,966 104,495 97,996
Durdans Heart Centre (Pvt) Ltd	Subsidiary	Sales of Drugs and consumables Rendering of medical services Sharing of utilities and other cost Dividend received  Purchases of Drugs and consumables Receiving of medical services Receiving of utilities and other cost	Recurrent Recurrent Recurrent  Recurrent Recurrent Recurrent	4,592 11,746 104,109 10,323  5,167 1,017 3,338
Amrak Institute of Medical Sciences (Pvt) Ltd	Subsidiary	Rent Received Providing utilities and other cost	Recurrent Recurrent	17,523 5,193
Ceygen Biotech (Pvt) Ltd	Subsidiary	Providing utilities and other cost Rent Received	Recurrent Recurrent	309 1,155
Commercial Marketing Distributors (Pvt) Ltd	Affiliate	Sale of Drugs and consumables  Purchases of Drugs and consumables	Recurrent  Recurrent	529  139,587
Tudawe Brothers (Pvt) Ltd	Affiliate	Diagnostic Service	Recurrent	77
Tudawe Engineering Services (Pvt) Ltd	Affiliate	Purchase of Equipment	Recurrent	2,680

Share Information

Number of Shares Represented in Stated Capital

Voting Shares	30,997,401
Non-Voting Shares	10,133,765
Total	<b>41,131,166</b>

The voting shares of 3,874,675 and the non voting shares of 1,266,721 issued through Rights issue in June 2024 that was listed on Colombo Stock Exchange on 03rd July 2024 has been included in the share information above.

Public Shareholding as at 31st December 2024

	Voting	Non-Voting
Number of shareholders	2,374	1,308
Number of shares	6,620,581	5,095,055
Holding Percentage	21.36%	50.28%
Float Adjusted Market Capitalisation (Rs Mn)	761	
Float Adjusted Market Capitalisation Option	Less than 2.5 Bn (Option 5)	

Directors' and Chief Executive Officer's Shareholding as at 31st December 2024

	Number of Shares	
	Voting	Non-Voting
Mr. A. E. Tudawe	397,830	-
Mr. A. D. Tudawe (Joint Account)	128,132	-
Mr. U. D. Tudawe	335,014	-
Dr A. D. P. A. Wijegoonewardene	268,743	-
Mr. Y. N. R. Piyasena	522,824	-
Mr. A. D. B. Talwatte	1,213	-
Mr. A.V.R. De Silva Jayatilleke	121	-
Mr. A.S. Tudawe	51	1,062
Mr. S. Renganathan	-	-
Mr. H.M.A. Jayasinghe	-	-

Market Prices recorded during the Quarter

	Highest Traded Price		Lowest Traded Price		Last Traded Price	
	2024/25 Rs.	2023/24 Rs.	2024/25 Rs.	2023/24 Rs.	2024/25 Rs.	2023/24 Rs.
Voting	<b>129.25</b> <i>30/07/2024</i>	141.75 <i>18/10/2023</i>	<b>110.00</b> <i>05/08/2024</i>	120.00 <i>29/12/2023</i>	<b>115.00</b> <i>31/12/2024</i>	120.00 <i>29/12/2023</i>
Non - Voting	<b>98.70</b> <i>18/07/2024</i>	121.00 <i>13/10/2023</i>	<b>87.00</b> <i>13/09/2024</i>	97.00 <i>04/10/2023</i>	<b>99.00</b> <i>31/12/2024</i>	104.00 <i>11/12/2023</i>

Per Share Ratios

	Group		Company	
	As at 31/12/2024 Rs.	As at 31/12/2023 Rs.	As at 31/12/2024 Rs.	As at 31/12/2023 Rs.
Earnings Per Share	<b>11.73</b>	6.08	<b>4.09</b>	4.55
Net Asset Per Share	<b>220.50</b>	219.75	<b>157.84</b>	160.68



**Top 20 Shareholders Listed as at 31st December 2024**

**Voting Shareholders**

	<b>Country of Residence</b>	<b>Number of Shares</b>	<b>Holding %</b>
Durdans Management Services Ltd	Sri Lanka	21,574,963	69.60
Mr. D.G. Wijemanna	do	738,623	2.38
Mr. R.P. Weerasooriya	do	701,457	2.26
Mr. Y. N. R. Piyasena	do	522,824	1.69
Mr. Deen Mohamed Fazal Aslam	do	519,000	1.67
Galle Face Capital Partners PLC	do	518,791	1.67
Mr. A. E. Tudawe	do	397,830	1.28
Mr. Merrill J. Fernando (Deceased)	do	390,500	1.26
Cargo Boat Development Company PLC	do	370,945	1.20
Mr. U. D. Tudawe	do	335,014	1.08
MJF Holdings (Pvt) Ltd	do	287,917	0.93
Dr. A. D. P. A. Wijegoonewardene	do	268,743	0.87
Mr. H. L. Tudawe	do	253,626	0.82
Mr. P.V. Tudawe	do	219,920	0.71
Mr. A. D. Tudawe (Joint Account)	do	196,694	0.63
Mr. G. A. Tudawe	do	140,130	0.45
Mr. A. D. Tudawe (Joint Account)	do	128,132	0.41
Mr. E. H. Tudawe	do	118,030	0.38
Mr. R. Y. Tudawe	do	112,015	0.36
Commercial Bank of Ceylon PLC A/C No. 04	do	88,187	0.28
		<b>27,883,341</b>	<b>89.96</b>

**Non-Voting Shareholders**

<b>Name of the Shareholder</b>	<b>Country of Residence</b>	<b>Number of Shares</b>	<b>Holding %</b>
Durdans Management Services Ltd	Sri Lanka	3,588,133	35.41
Employees' Provident Fund	do	1,154,371	11.39
MJF Holdings (Pvt) Ltd	do	636,061	6.28
E. W. Balasuriya & Co. (Pvt) Ltd	do	401,465	3.96
Mr. D. Ratnayake	do	156,045	1.54
Mr. L.J.M.A. Jayasundara	do	150,500	1.49
Tudawe Engineering Services (Pvt) Ltd	do	111,697	1.10
Mr. D. A. Cabraal	do	100,178	0.99
Mr. A. H. Munasinghe	do	98,141	0.97
Mr. S. S. Sithambaranathan	do	94,357	0.93
Mr. A. D. Tudawe	do	86,396	0.85
Ms. T. T. Weerasinghe	do	80,554	0.79
Mr. D. G. Wijemanna	do	77,728	0.77
Mr. P. S. De Mel	do	75,248	0.74
Peoples Leasing & Finance PLC /Mr. P. A. I. S. Perera	do	72,857	0.72
Saman Villas Limited	do	70,988	0.70
Commercial Bank of Ceylon PLC A/C No. 04	do	64,918	0.64
Mr. G. D. M. Ranasinghe	do	62,857	0.62
Mr. D.P. L. De Mel	do	62,589	0.62
Mr. A. H. Munasinghe	do	61,269	0.60
		<b>7,206,352</b>	<b>71.11</b>

# CEYLON HOSPITALS PLC

## CORPORATE INFORMATION

### **Name of Company**

Ceylon Hospitals PLC

### **Brand Name**

DURDANS

### **Legal Form**

A quoted public company with limited liability incorporated in Sri Lanka under the Companies Ordinance No.51 of 1938 and registered under the Companies Act No.07 of 2007.

### **Stocks Exchange Listing**

The Ordinary Shares of the Company are listed on the Colombo Stock Exchange of Sri Lanka.

### **Registered Office**

No.03, Alfred Place, Colombo 03.

### **Bankers**

Bank of Ceylon  
Commercial Bank of Ceylon PLC  
DFCC Bank PLC  
Hatton National Bank PLC  
National Development Bank PLC  
Nations Trust Bank PLC  
Sampath Bank PLC  
Seylan Bank PLC  
Union Bank of Colombo PLC  
People's Bank

### **Auditors**

Messers.B.R.De.Silva & Co.  
Chartered Accountants  
No. 22/4,Vijaya Kumaratunga Mawatha  
Colombo 05.

### **Lawyers**

Mr. D.F.R. Jayamaha  
Hector Jayamaha Law Office,  
No.228,Thimbirigasyaya Road,  
Colombo 05.

### **Secretaries**

Nexia Corporate Consultants (Pvt) Ltd  
No. 130, Level 02, Nawala Road,  
Narahenpita. Colombo 05.

546, Galle Road,  
Colombo 03.



**CEYLON HOSPITALS PLC**

3 Alfred Place Colombo 3 Sri Lanka

**T** +94 (0) 11 2 140 000 **F** +94 (0) 11 2 575 302 **E** [contactus@durdans.com](mailto:contactus@durdans.com) **W** [durdans.com](http://durdans.com)

*Dedicated to you*